R J Straka

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. pmc High-fat meal effect on LDL, HDL, and VLDL particle size and number in the Genetics of Lipid-Lowering Drugs and Diet Network (GOLDN): an interventional study
    Mary K Wojczynski
    Department of Biostatistics, University of Alabama at Birmingham, Brimingham, AL, USA
    Lipids Health Dis 10:181. 2011
  2. pmc Determining initial and follow-up costs of cardiovascular events in a US managed care population
    Richard H Chapman
    US Health Economics and Outcomes Research, IMS Health, Falls Church, VA, USA
    BMC Cardiovasc Disord 11:11. 2011
  3. pmc Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting
    Robert J Straka
    Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN, USA
    Cardiovasc Diabetol 8:53. 2009
  4. ncbi request reprint Assessment of hypercholesterolemia control in a managed care organization
    R J Straka
    College of Pharmacy, University of Minnesota, Minneapolis, 55455, USA
    Pharmacotherapy 21:818-27. 2001
  5. ncbi request reprint Determination of fenofibric acid concentrations by HPLC after anion exchange solid-phase extraction from human serum
    Robert J Straka
    University of Minnesota College of Pharmacy, Department of Experimental and Clinical Pharmacology, Minneapolis, Minnesota, USA
    Ther Drug Monit 29:197-202. 2007
  6. ncbi request reprint Discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects
    Robert J Straka
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455 0353, USA
    J Clin Pharmacol 46:802-11. 2006
  7. ncbi request reprint Achieving cholesterol target in a managed care organization (ACTION) trial
    Robert J Straka
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Pharmacotherapy 25:360-71. 2005
  8. ncbi request reprint Verified predominance of slow acetylator phenotype N-acetyltransferase 2 (NAT2) in a Hmong population residing in Minnesota
    Robert J Straka
    University of Minnesota, Department of Experimental and Clinical Pharmacology, 7 109 Weaver Densford Hall, Minneapolis, MN 55455 0353, USA
    Biopharm Drug Dispos 27:299-304. 2006
  9. pmc Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network
    Michael Y Tsai
    Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455 0392, USA
    Mol Genet Metab 100:118-22. 2010
  10. ncbi request reprint Effect of influenza vaccine on markers of inflammation and lipid profile
    Michael Y Tsai
    Laboratory of Medicine and Pathology, University of Minnesota, Minneapolis, USA
    J Lab Clin Med 145:323-7. 2005

Collaborators

Detail Information

Publications18

  1. pmc High-fat meal effect on LDL, HDL, and VLDL particle size and number in the Genetics of Lipid-Lowering Drugs and Diet Network (GOLDN): an interventional study
    Mary K Wojczynski
    Department of Biostatistics, University of Alabama at Birmingham, Brimingham, AL, USA
    Lipids Health Dis 10:181. 2011
    ..Analyses were stratified by baseline triglycerides (normal vs. elevated) and gender. The effect of PPL on changes in lipoprotein subclasses was assessed using repeated measures ANOVA...
  2. pmc Determining initial and follow-up costs of cardiovascular events in a US managed care population
    Richard H Chapman
    US Health Economics and Outcomes Research, IMS Health, Falls Church, VA, USA
    BMC Cardiovasc Disord 11:11. 2011
    ..This study aims to determine initial and follow-up costs for cardiovascular (CV) events in US managed care enrollees and to compare to healthcare costs for matched patients without CV events...
  3. pmc Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting
    Robert J Straka
    Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN, USA
    Cardiovasc Diabetol 8:53. 2009
    ..We conducted a retrospective claims database analysis to evaluate incremental cardiovascular costs in diabetic versus non-diabetic patients hospitalized for a cardiovascular event...
  4. ncbi request reprint Assessment of hypercholesterolemia control in a managed care organization
    R J Straka
    College of Pharmacy, University of Minnesota, Minneapolis, 55455, USA
    Pharmacotherapy 21:818-27. 2001
    ..Finally, the successful merging of medical, laboratory, and pharmacy claims databases provides a benchmark for other institutions...
  5. ncbi request reprint Determination of fenofibric acid concentrations by HPLC after anion exchange solid-phase extraction from human serum
    Robert J Straka
    University of Minnesota College of Pharmacy, Department of Experimental and Clinical Pharmacology, Minneapolis, Minnesota, USA
    Ther Drug Monit 29:197-202. 2007
    ..This method is suitable for quantification of fenofibric acid for clinical pharmacokinetic studies in patients with dyslipidemia...
  6. ncbi request reprint Discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects
    Robert J Straka
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455 0353, USA
    J Clin Pharmacol 46:802-11. 2006
    ..Environmental, genetic, or phenotypic anomalies that may contribute to this discordance should be considered and evaluated in future studies within this unique population...
  7. ncbi request reprint Achieving cholesterol target in a managed care organization (ACTION) trial
    Robert J Straka
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Pharmacotherapy 25:360-71. 2005
    ....
  8. ncbi request reprint Verified predominance of slow acetylator phenotype N-acetyltransferase 2 (NAT2) in a Hmong population residing in Minnesota
    Robert J Straka
    University of Minnesota, Department of Experimental and Clinical Pharmacology, 7 109 Weaver Densford Hall, Minneapolis, MN 55455 0353, USA
    Biopharm Drug Dispos 27:299-304. 2006
    ..The predominance of the SA phenotype within Minnesota Hmong is confirmed. Further studies evaluating this unexpected prevalence, its genetic basis and potential clinical relevance to drug toxicity and disease are warranted...
  9. pmc Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network
    Michael Y Tsai
    Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455 0392, USA
    Mol Genet Metab 100:118-22. 2010
    ....
  10. ncbi request reprint Effect of influenza vaccine on markers of inflammation and lipid profile
    Michael Y Tsai
    Laboratory of Medicine and Pathology, University of Minnesota, Minneapolis, USA
    J Lab Clin Med 145:323-7. 2005
    ..Consequently, clinical and epidemiologic interpretation of the biomarkers affected should take into account the possible effects of influenza vaccination...
  11. ncbi request reprint Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective
    Robert J Straka
    University of Minnesota, Minneapolis, MN, USA
    Curr Med Res Opin 23:1517-29. 2007
    ..The present analysis modeled the clinical and economic consequences of initiating atorvastatin versus generic simvastatin in defined US managed care organization patient populations...
  12. ncbi request reprint Mixture models and subpopulation classification: a pharmacokinetic simulation study and application to metoprolol CYP2D6 phenotype
    Nitin Kaila
    Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA
    J Pharmacokinet Pharmacodyn 34:141-56. 2007
    ..In a population pharmacokinetic analysis of metoprolol, a drug that undergoes polymorphic metabolism, it was possible to correctly identify phenotype status using a mixture model...
  13. pmc The effect of IL6-174C/G polymorphism on postprandial triglyceride metabolism in the GOLDN studyboxs
    Jian Shen
    Nutrition and Genomics Laboratory, Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA
    J Lipid Res 49:1839-45. 2008
    ..This phenomenon could be responsible for the observed association of this genetic variant with cardiovascular disease risk...
  14. doi request reprint The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions
    Yongjun Liu
    Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA
    J Hum Genet 53:709-17. 2008
    ..In summary, our study suggested that the SCARB1 gene may serve as a useful marker that predicts variation in baseline lipid levels, postprandial lipid response, and response to fenofibrate intervention...
  15. pmc The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment
    Jennifer A Smith
    Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI 48109 2029, USA
    Eur J Hum Genet 16:603-13. 2008
    ..These results yield insight into the complex biology of fenofibrate response, which can be used to target fenofibrate therapy to individuals who are most likely to benefit from the drug...
  16. ncbi request reprint Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study
    Chao Qiang Lai
    Nutrition and Genomics Laboratory, JM USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington St, Boston, MA 02111, USA
    Arterioscler Thromb Vasc Biol 27:1417-25. 2007
    ..Apolipoprotein A5 (APOA5) is a key determinant of plasma triglyceride (TG) concentrations. Genetic variation at the APOA5 locus could be responsible for some of the observed differences in response to fenofibrate therapy...
  17. doi request reprint Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study
    Jian Shen
    Nutrition and Genomics Laboratory, Jean Mayer U S Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts 02111 1524, USA
    Diabetes Care 31:910-5. 2008
    ..We investigated the influences of CRP polymorphisms on baseline CRP levels and fenofibrate-induced CRP changes in subjects with the metabolic syndrome...
  18. ncbi request reprint The -256T>C polymorphism in the apolipoprotein A-II gene promoter is associated with body mass index and food intake in the genetics of lipid lowering drugs and diet network study
    Dolores Corella
    Nutrition and Genomics Laboratory, Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA 02111 1524, USA
    Clin Chem 53:1144-52. 2007
    ..Apolipoprotein A-II (APOA2) plays an ambiguous role in lipid metabolism, obesity, and atherosclerosis...